CHO microRNA engineering is growing up: Recent successes and future challenges☆

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

microRNAs with their ability to regulate complex pathways that control cellular behavior and phenotype have been proposed as potential targets for cell engineering in the context of optimization of biopharmaceutical production cell lines, specifically of Chinese Hamster Ovary cells. However, until recently, research was limited by a lack of genomic sequence information on this industrially important cell line. With the publication of the genomic sequence and other relevant data sets for CHO cells since 2011, the doors have been opened for an improved understanding of CHO cell physiology and for the development of the necessary tools for novel engineering strategies. In the present review we discuss both knowledge on the regulatory mechanisms of microRNAs obtained from other biological models and proof of concepts already performed on CHO cells, thus providing an outlook of potential applications of microRNA engineering in production cell lines.

Related collections

Most cited references 166

Record: found
Abstract: found
Article: not found

MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.

Jennifer A. Chan, Anna Krichevsky, Kenneth S. Kosik (2005)

MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by targeting the mRNA of protein-coding genes for either cleavage or repression of translation. The roles of miRNAs in lineage determination and proliferation as well as the location of several miRNA genes at sites of translocation breakpoints or deletions has led to the speculation that miRNAs could be important factors in the development or maintenance of the neoplastic state. Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21. Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells. Knockdown of miR-21 in cultured glioblastoma cells triggers activation of caspases and leads to increased apoptotic cell death. Our data suggest that aberrantly expressed miR-21 may contribute to the malignant phenotype by blocking expression of critical apoptosis-related genes.

0 comments Cited 640 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

miR-21-mediated tumor growth.

M-L Si, S Zhu, H. Wu … (2007)

MicroRNAs (miRNAs) are approximately 22 nucleotide non-coding RNA molecules that regulate gene expression post-transcriptionally. Although aberrant expression of miRNAs in various human cancers suggests a role for miRNAs in tumorigenesis, it remains largely unclear as to whether knockdown of a specific miRNA affects tumor growth. In this study, we profiled miRNA expression in matched normal breast tissue and breast tumor tissues by TaqMan real-time polymerase chain reaction miRNA array methods. Consistent with previous findings, we found that miR-21 was highly overexpressed in breast tumors compared to the matched normal breast tissues among 157 human miRNAs analysed. To better evaluate the role of miR-21 in tumorigenesis, we transfected breast cancer MCF-7 cells with anti-miR-21 oligonucleotides and found that anti-miR-21 suppressed both cell growth in vitro and tumor growth in the xenograft mouse model. Furthermore, this anti-miR-21-mediated cell growth inhibition was associated with increased apoptosis and decreased cell proliferation, which could be in part owing to downregulation of the antiapoptotic Bcl-2 in anti-miR-21-treated tumor cells. Together, these results suggest that miR-21 functions as an oncogene and modulates tumorigenesis through regulation of genes such as bcl-2 and thus, it may serve as a novel therapeutic target.

0 comments Cited 451 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

MiR-33 contributes to the regulation of cholesterol homeostasis.

Katey Rayner, Yajaira Suárez, Alberto Davalos … (2010)

Cholesterol metabolism is tightly regulated at the cellular level. Here we show that miR-33, an intronic microRNA (miRNA) located within the gene encoding sterol-regulatory element-binding factor-2 (SREBF-2), a transcriptional regulator of cholesterol synthesis, modulates the expression of genes involved in cellular cholesterol transport. In mouse and human cells, miR-33 inhibits the expression of the adenosine triphosphate-binding cassette (ABC) transporter, ABCA1, thereby attenuating cholesterol efflux to apolipoprotein A1. In mouse macrophages, miR-33 also targets ABCG1, reducing cholesterol efflux to nascent high-density lipoprotein (HDL). Lentiviral delivery of miR-33 to mice represses ABCA1 expression in the liver, reducing circulating HDL levels. Conversely, silencing of miR-33 in vivo increases hepatic expression of ABCA1 and plasma HDL levels. Thus, miR-33 appears to regulate both HDL biogenesis in the liver and cellular cholesterol efflux.

0 comments Cited 387 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Biotechnol Adv

Journal ID (iso-abbrev): Biotechnol. Adv

Title: Biotechnology Advances

Publisher: Elsevier Science

ISSN (Print): 0734-9750

ISSN (Electronic): 1873-1899

Publication date PMC-release: 1 December 2013

Publication date (Print): December 2013

Volume: 31

Issue: 8

Pages: 1501-1513

Affiliations

[a ]Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria

[b ]Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Bldg 14A, Bethesda, MD 20892, USA

[c ]Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA

[d ]Life Sciences, University of Warwick, UK

[e ]National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland

[f ]Austrian Center of Industrial Biotechnology, Austria

Author notes

[* ]Corresponding author.

[** ]Correspondence to: N. Borth, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria. Tel.: + 43 1 47654 6232; fax: + 43 1 47654 6675. nicole.borth@ 123456boku.ac.at

Article

Publisher ID: S0734-9750(13)00121-3

DOI: 10.1016/j.biotechadv.2013.07.007

PMC ID: 3854872

PubMed ID: 23916872

SO-VID: 380fa938-8717-4ae8-8625-929b681d12ca

License:

This document may be redistributed and reused, subject to certain conditions.

History

Date received : 11 March 2013

Date revision received : 18 July 2013

Date accepted : 20 July 2013

Comments

Comment on this article

scite_

Cited by 20

See all cited by

Most referenced authors 3,185

See all reference authors

- Version 1